Innovent Reports Positive Results for PD-1 Candidate; Files China NDA

Published on: May 17, 2018
Author: Amy Liu

Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, sintilimab (IBI308). In 96 patients with relapsed/refractory classical Hodgkin Lymphoma, sintilimab produced an overall response rate of 79% and a disease control rate of 98%, meeting the endpoints of the study. Innovent said it submitted an NDA to the CFDA for sintilimab on April 19, 2018, which will be reviewed following speeded-up Priority Review rules.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical